Flubendazole suppresses VEGF-induced angiogenesis in HUVECs and exerts antitumor effects in PC-3 cells

Flubendazole, an FDA-approved anthelmintic, has been predicted to show strong VEGFR2/KDR/Flk-1 inhibitory activity in silico screening combined with in vitro experimental validation, and it has shown anti-cancer effects on some human Cancer cell lines, but little is known about the anti-angiogenesis effects and anti-prostate Cancer effects. In this study, we analyzed the binding modes and kinetic analysis of flubendazole with VEGFR2/KDR/Flk-1 and first demonstrated that flubendazole suppressed VEGF-stimulated cell proliferation, wound-healing migration, cell invasion and tube formation of HUVEC cells, and decreased the phosphorylation of extracellular signal-regulated kinase and serine/threonine kinase Akt, which are the downstream proteins of VEGFR2/KDR/Flk-1 that are important for cell growth. What's more, our results showed that flubendazole decreased PC-3 cell viability and proliferation ability, and suppressed PC-3 cell wound healing migration and invasion across a Matrigel-coated Transwell membrane in a concentration-dependent manner. The antiproliferative effects of flubendazole were due to induction of G2-M phase cell cycle arrest in PC-3 cells with decreasing expression of the Cyclin D1 and induction of cell Apoptosis with the number of apoptotic cells increased after flubendazole treatment. These results indicated that flubendazole could exert anti-angiogenic and Anticancer effects by inhibiting cell cycle and inducing cell Apoptosis.

VEGFR2; angiogenesis; flubendazole; prostate cancer.